Make an Appointment
John Theurer Cancer Center Participating in EarlyPhase Study of ImmunotherapyBoosting Treatment
![](/-/media/Project/HMH/HMH/MAESTRO/wp-content/uploads/clinical-trial.jpg)
What you need to know
Investigators at John Theurer Cancer Center at Hackensack University Medical are participating in a first-in-patients clinical trial assessing VE800, a novel bacteria-containing therapy, in combination with the immunotherapy drug nivolumab. Laboratory research has suggested that VE800 may enhance the effectiveness of drugs like nivolumab. The phase I study will evaluate the safety and clinical activity of VE800 in combination with nivolumab in patients with advanced or metastatic melanoma, gastric/gastroesophageal junction adenocarcinoma (esophagus/stomach cancer), or a type of colon cancer called microsatellite-stable colorectal cancer. The first results are anticipated in 2021. Nivolumab belongs to the checkpoint inhibitors class of drugs which also include pembrolizumab and ipilimumab.